Does high-grade endometrioid carcinoma (grade 3 FIGO) belong to type I or type II endometrial cancer? A clinical-pathological and immunohistochemical study - PubMed (original) (raw)

Does high-grade endometrioid carcinoma (grade 3 FIGO) belong to type I or type II endometrial cancer? A clinical-pathological and immunohistochemical study

Gian Franco Zannoni et al. Virchows Arch. 2010 Jul.

Abstract

This study was aimed at determining whether high-grade endometrioid carcinomas (grade 3 International Federation of Gynecology and Obstetrics) might overlap, at least partially, non-endometrioid carcinomas (type II). To this end, a panel of clinical-pathological and immunohistochemical parameters was evaluated in three different populations: low-grade endometrioid carcinomas (LGECs; n = 57), high-grade endometrioid carcinomas (HGECs; n = 26), and non-endometrioid carcinomas (NECs; n = 30). Besides morphological appearance, HGECs appeared similar to LGECs in p53 immunostaining profile; features different from LGECs included a higher local aggressiveness, a higher invasion of lymph-vascular spaces, a lower expression of ERalpha and PR, and a higher proliferative index. HGECs were similar to NECs for local aggressiveness, invasion rate of lymph-vascular spaces, lymph node metastasis incidence, and proliferative index. HGECs, however, showed a lower rate of extra-nodal metastases, a lower incidence of p53 overexpression, and a higher positivity for ERalpha and PR. In conclusion, results from this study show that HGECs exhibit overlapping morphological and immunohistochemical features of both type I and type II endometrial carcinomas. Further research is needed to clarify the clinical value of this observation.

PubMed Disclaimer

Similar articles

• Serous endometrial cancers that mimic endometrioid adenocarcinomas: a clinicopathologic and immunohistochemical study of a group of problematic cases.
  Darvishian F, Hummer AJ, Thaler HT, Bhargava R, Linkov I, Asher M, Soslow RA. Darvishian F, et al. Am J Surg Pathol. 2004 Dec;28(12):1568-78. doi: 10.1097/00000478-200412000-00004. Am J Surg Pathol. 2004. PMID: 15577675
• Comparative immunohistochemical study of endometrioid and serous papillary carcinoma of endometrium.
  Halperin R, Zehavi S, Habler L, Hadas E, Bukovsky I, Schneider D. Halperin R, et al. Eur J Gynaecol Oncol. 2001;22(2):122-6. Eur J Gynaecol Oncol. 2001. PMID: 11446475
• Clear cell carcinoma of the endometrium is characterized by a distinctive profile of p53, Ki-67, estrogen, and progesterone receptor expression.
  Lax SF, Pizer ES, Ronnett BM, Kurman RJ. Lax SF, et al. Hum Pathol. 1998 Jun;29(6):551-8. doi: 10.1016/s0046-8177(98)80002-6. Hum Pathol. 1998. PMID: 9635673
• High-grade Endometrial Carcinomas: Morphologic and Immunohistochemical Features, Diagnostic Challenges and Recommendations.
  Murali R, Davidson B, Fadare O, Carlson JA, Crum CP, Gilks CB, Irving JA, Malpica A, Matias-Guiu X, McCluggage WG, Mittal K, Oliva E, Parkash V, Rutgers JKL, Staats PN, Stewart CJR, Tornos C, Soslow RA. Murali R, et al. Int J Gynecol Pathol. 2019 Jan;38 Suppl 1(Iss 1 Suppl 1):S40-S63. doi: 10.1097/PGP.0000000000000491. Int J Gynecol Pathol. 2019. PMID: 30550483 Free PMC article. Review.
• A dualistic model for endometrial carcinogenesis based on immunohistochemical and molecular genetic analyses.
  Lax SF, Kurman RJ. Lax SF, et al. Verh Dtsch Ges Pathol. 1997;81:228-32. Verh Dtsch Ges Pathol. 1997. PMID: 9474874 Review.

Cited by

• Association of insulin-like growth factor II mrna-binding protein 3 (IMP3) expression with prognostic and morphological factors in endometrial cancer.
  Salum SOR, Candido EB, Domingues MAC, Ojopi EPB, Tonon ÂFS, da Silva-Filho AL. Salum SOR, et al. Rev Bras Ginecol Obstet. 2024 Jul 26;46:e-rbgo61. doi: 10.61622/rbgo/2024rbgo61. eCollection 2024. Rev Bras Ginecol Obstet. 2024. PMID: 39176196 Free PMC article.
• Determination of endometrial cancer molecular subtypes using a whole exome-sequencing based single-method approach.
  Mustea A, Ralser DJ, Egger EK, Ziehm U, Vivas S, Brock S, Jackson D, Condic M, Rauschendorf MA, Würfel P, Dombrowski F, Otten LA, Sun P, Laib A, Cordova MC, Hartmann R, Stein MA, Koensgen D, Stope MB. Mustea A, et al. J Cancer Res Clin Oncol. 2024 Jul 25;150(7):367. doi: 10.1007/s00432-024-05901-4. J Cancer Res Clin Oncol. 2024. PMID: 39052171 Free PMC article.
• The Advantages of Next-Generation Sequencing Molecular Classification in Endometrial Cancer Diagnosis.
  Rivera D, Paudice M, Accorsi G, Valentino F, Ingaliso M, Pianezzi A, Roggieri P, Trevisan L, Buzzatti G, Mammoliti S, Barra F, Ferrero S, Cirmena G, Gismondi V, Vellone VG. Rivera D, et al. J Clin Med. 2023 Nov 22;12(23):7236. doi: 10.3390/jcm12237236. J Clin Med. 2023. PMID: 38068290 Free PMC article.
• Histopathological and Immunohistochemical Prognostic Factors in High-Grade Non-Endometrioid Carcinomas of the Endometrium (HG-NECs): Is It Possible to Identify Subgroups at Increased Risk?
  Paudice M, Biatta CM, Scaglione G, Parodi A, Mammoliti S, Moioli M, Centurioni MG, Barra F, Ferrero S, De Cian F, Mazzocco K, Vellone VG. Paudice M, et al. Diagnostics (Basel). 2023 Jun 26;13(13):2171. doi: 10.3390/diagnostics13132171. Diagnostics (Basel). 2023. PMID: 37443564 Free PMC article.
• The value of magnetic resonance imaging-based tumor shape features for assessing microsatellite instability status in endometrial cancer.
  Wang H, Xu Z, Zhang H, Huang J, Peng H, Zhang Y, Liang C, Zhao K, Liu Z. Wang H, et al. Quant Imaging Med Surg. 2022 Sep;12(9):4402-4413. doi: 10.21037/qims-22-77. Quant Imaging Med Surg. 2022. PMID: 36060586 Free PMC article.

References

1. 1. Gynecol Oncol. 2004 Apr;93(1):34-40 - PubMed
2. 1. Hum Pathol. 1995 Nov;26(11):1268-74 - PubMed
3. 1. Cancer Control. 2009 Jan;16(1):46-52 - PubMed
4. 1. Hum Pathol. 1998 Sep;29(9):924-31 - PubMed
5. 1. Cancer Control. 2009 Jan;16(1):8-13 - PubMed

MeSH terms

Substances

LinkOut - more resources

• Full Text Sources

  • Springer

• Research Materials

  • NCI CPTC Antibody Characterization Program

• Miscellaneous

  • NCI CPTAC Assay Portal